"L’Institut de Cancérologie Paris Nord est l'un des centres de référence en radiothérapie du Val d’Oise (95). Il se situe à Sarcelles, au sein d’un important complexe médical, et collabore avec plusieurs établissements privés du territoire pour assurer la prise en charge en chirurgie, chimiothérapie et soins de suite en cancérologie."

During the past decade, Institut de Cancérologie Paris Nord conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut de Cancérologie Paris Nord" #1 sponsor was "Centre Oscar Lambret" with 3 trials, followed by "UNICANCER" with 2 trials sponsored, "ARCAGY/ GINECO GROUP" with 1 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 1 trials sponsored and "Federation Francophone de Cancerologie Digestive" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut de Cancérologie Paris Nord" #1 collaborator was "Aquilab SAS" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Canceropôle Nord Ouest" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "Federation Francophone de Cancerologie Digestive" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Institut de Cancérologie Paris Nord" are "Breast Cancer" (2 trials), "Prostate Cancer" (2 trials), "Breast Ductal Carcinoma In Situ" (1 trials), "Colorectal Neoplasms" (1 trials) and "Digestive Oncology" (1 trials). Many other conditions were trialed in "Institut de Cancérologie Paris Nord" in a lesser frequency.

Most popular intervention types in "Institut de Cancérologie Paris Nord" are "Drug" (6 trials), "Radiation" (4 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Anastrozole" (1 trials), "Androgen Deprivation Therapy" (1 trials), "Apalutamide" (1 trials), "Biodegradable balloon implant" (1 trials) and "DONEPEZIL" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut de Cancérologie Paris Nord" are 4 trials for "Female" genders, 3 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Institut de Cancérologie Paris Nord". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Institut de Cancérologie Paris Nord, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institut de Cancérologie Paris Nord, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".